

UNITED STATES DEPARTMENT OF COMMERCE United States Pat int and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/528,644	03/20/00	THIM	L	3951.224-05

HM12/0425

STEVE T ZELSON ESQ NOVO NORDISK OF NORTH AMERICA INC 405 LEXINGTON AVENUE SUITE 6400 NEW YORK NY 10017

		EXAMINER
	RUMEU,	Li

ART UNIT PAPER NUMBER

DATE MAILED:

04/25/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks



1

Office Action Summary

Application No. 09/528,644

Applicant(s)

Examiner

David Romeo

Group Art Unit 1647

Thim et al.



X Responsive to communication(s) filed on 20 Mar 2000							
☐ This action is FINAL .							
Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.							
A shortened statutory period for response to this action is set to expire1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).							
Disposition of Claims							
	is/are pending in the application.						
Of the above, claim(s)	is/are withdrawn from consideration.						
Claim(s)	is/are allowed.						
Claim(s)	is/are rejected.						
Claim(s)							
Application Papers							
\square See the attached Notice of Draftsperson's Patent Drawing	Review, PTO-948.						
☐ The drawing(s) filed on is/are objecte	d to by the Examiner.						
☐ The proposed drawing correction, filed on	is approved disapproved.						
\square The specification is objected to by the Examiner.							
☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. § 119							
☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).							
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been							
☐ received.							
received in Application No. (Series Code/Serial Number)							
#O colling and a section was assessed.	☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).						
☐ Acknowledgement is made of a claim for domestic priority	under 35 U.S.C. § 119(e).						
Attachment(s)							
☐ Notice of References Cited, PTO-892							
☐ Information Disclosure Statement(s), PTO-1449, Paper No(s)							
☐ Interview Summary, PTO-413 ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948 ☐ Nation of Informal Patent Application, PTO 153							
					☐ Notice of Informal Patent Application, PTO-152		
Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures							
SEE OFFICE ACTION ON THE FOLLOWING PAGES							

Application/Control Number: 09528644 Page 2

Art Unit: 1647

5

10

15

DETAILED ACTION

1. The numbering of claims is not accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not).

Misnumbered claims 28-39 have been renumbered 27-38.

Election/Restriction

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 27-33, 36, drawn to a human spamolytic polypeptide, classified in class530, subclass 350.
 - II. Claims 34, 35, 38, drawn to a recombinant method of producing a human spamolytic polypeptide, classified in class 435, subclass 69.1.
 - III. Claim 37, drawn to a method of treating GI disorders with a human spamolytic polypeptide, classified in class 514, subclass 12.
- 3. The inventions are distinct, each from the other because of the following reasons:

Application/Control Number: 09528644

Art Unit: 1647

5

10

15

Inventions II and I are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the product as claimed can be made by extraction from human tissue.

Page 3

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process for using the product as claimed can be practiced with an antacid compound. Alternatively, the product as claimed can be used in an immunization protocol for the production of antibodies or can be used in an assay to identify agonists and antagonists of the product.

The following pairwise combinations of methods are independent and distinct, wherein each member of a pair performs different functions, using different starting materials and/or process steps and/or with different outcomes: II and III.

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Application/Control Number: 09528644

Art Unit: 1647

5. Because these inventions are distinct for the reasons given above and the searches required

Page 4

are not coextensive, restriction for examination purposes as indicated is proper.

6. Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art because of their recognized divergent subject matter, restriction for

examination purposes as indicated is proper.

7. Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37

CFR 1.143).

5

10

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(i).

Sequence Rule Compliance

15 9. This application contains sequence disclosures that are encompassed by the definitions for

nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However,

this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the

reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications

09528644.004

Art Unit: 1647

Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. See M.P.E.P § 2422.05 for invoking the procedures of 37 C.F.R. § 1.821(e) for using an identical computer readable form from another application.

ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (703) 305-4050. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 6:45 A.M. TO 3:15 P.M.

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

OFFICIAL PAPERS FILED BY FAX SHOULD BE DIRECTED TO (703) 308-4242.

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294.

ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.

DAVID ROMEO
PRIMARY EXAMINER
ART UNIT 1647

15

5

10

APRIL 24, 2001